BeOne Medicines (ONC) Cash & Equivalents (2015 - 2026)

BeOne Medicines (ONC) has reported Cash & Equivalents for 12 consecutive years, with $4.8 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents rose 90.42% year-over-year to $4.8 billion; the TTM figure through Mar 2026 stood at $4.8 billion (up 90.42% YoY), while the FY2025 annual figure was $4.5 billion, up 73.08% from the prior year.
• Cash & Equivalents rose to $4.8 billion in Q1 2026 per ONC's latest filing, from $4.5 billion in the prior quarter.
• Across five years, Cash & Equivalents topped out at $4.8 billion in Q1 2026 and bottomed at $191000.0 in Q3 2022.
• Historically, Cash & Equivalents has averaged $3.0 billion across 5 years, with a median of $3.1 billion in 2023.
• Annual changes were most pronounced in 2022 — Cash & Equivalents plunged 99.99% — and 2023, when it soared 1605835.08%.
• BeOne Medicines' Cash & Equivalents stood at $3.9 billion in 2022, then declined by 18.03% to $3.2 billion in 2023, then fell by 17.16% to $2.6 billion in 2024, then surged by 73.08% to $4.5 billion in 2025, then climbed by 5.37% to $4.8 billion in 2026.
• Business Quant data shows ONC's Cash & Equivalents at $4.8 billion in Q1 2026, $4.5 billion in Q4 2025, and $4.0 billion in Q3 2025.